Education
About Us
Working with TipRanks
Follow Us
Demant (WILYY)
OTHER OTC:WILYY
WILYY Stock Chart & Stats
$17.22
$0.87(4.68%)
At close: 4:00 PM EST
$17.22
$0.87(4.68%)
Day’s Range― - ―
52-Week Range$13.97 - $22.17
Previous CloseN/A
Volume404.00
Average Volume (3M)4.00
Market Cap
$6.12B
Enterprise Value$60.63B
Total Cash (Recent Filing)$1.33B
Total Debt (Recent Filing)$20.99B
Price to Earnings (P/E)26.1
Beta0.84
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding427,589,320
10 Day Avg. Volume0
30 Day Avg. Volume4
Financial Highlights & Ratios
PEG Ratio-0.80
Price to Book (P/B)4.48
Price to Sales (P/S)1.92
P/FCF Ratio13.87
Enterprise Value/Market Cap9.91
Enterprise Value/Revenue2.64
Enterprise Value/Gross Profit3.48
Enterprise Value/Ebitda11.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA sustained gross margin around 75.6% indicates durable product economics and structural pricing power in core hearing-aid products and instruments. High gross margins give the company room to absorb SG&A, fund R&D and support margin recovery even if ASPs or mix shift temporarily.
Strong Cash GenerationConsistently high free-cash-flow conversion (~84% of net income) and multi-billion DKK FCF provide a durable source for deleveraging, capex, and integration funding. Even with a modest FCF decline, strong conversion supports strategic flexibility and funds the 2026 cost program.
Expanded Hearing-care Footprint (KIND)Closing KIND materially increases retail scale (Germany leadership), broadens recurring service revenues and clinic reach, and adds predictable EBIT contribution. The acquisition strengthens market position and cross-sell potential, supporting structurally higher recurring margins over coming years.
Bears Say
Elevated LeverageMaterial rise in net debt and a 3.4x gearing level reduces financial flexibility and raises refinancing risk. Management paused buybacks to prioritize deleveraging, which constrains capital allocation and increases vulnerability to prolonged margin shortfalls or adverse FX movements.
Weakened Operating ProfitabilitySignificant margin compression reflects higher operating costs, adverse mix/ASP effects and one-offs; this reduces the company's ability to convert revenue into sustainable operating earnings. Restoring margins requires successful execution of cost programs and stable top-line trends.
Market Softness & Competitive PressureStructural channel shifts and intensified competition (large retailers expanding suppliers, low-price in-ear launches) pressure ASPs and share in key markets like the U.S. Persistent share loss or sustained pricing pressure would constrain long-term revenue growth and margin recovery.
Demant News
WILYY FAQ
What was Demant’s price range in the past 12 months?
Demant lowest stock price was $13.97 and its highest was $22.17 in the past 12 months.
What is Demant’s market cap?
Demant’s market cap is $6.12B.
When is Demant’s upcoming earnings report date?
Demant’s upcoming earnings report date is Aug 18, 2026 which is in 176 days.
How were Demant’s earnings last quarter?
Demant released its earnings results on Feb 03, 2026. The company reported $0.159 earnings per share for the quarter, beating the consensus estimate of N/A by $0.159.
Is Demant overvalued?
According to Wall Street analysts Demant’s price is currently Overvalued.
Does Demant pay dividends?
Demant does not currently pay dividends.
What is Demant’s EPS estimate?
Demant’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Demant have?
Demant has 427,589,320 shares outstanding.
What happened to Demant’s price movement after its last earnings report?
Demant reported an EPS of $0.159 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -10.588%.
Which hedge fund is a major shareholder of Demant?
Currently, no hedge funds are holding shares in WILYY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Demant Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.03%
12-Months-Change
Fundamentals
Return on Equity
27.42%
Trailing 12-Months
Asset Growth
10.32%
Trailing 12-Months
Company Description
Demant
Demant A/S, a hearing healthcare and audio technology company, develops, manufactures, and sells products and equipment to enhance people's hearing in Europe, North America, the Pacific, Asia, and internationally. It operates in two segments, Hearing Healthcare and Communications. The Hearing Healthcare segment offers hearing implants and aids, hearing care, and diagnostic products. The Communications segment provides headsets for collaborative work and gaming markets under the EPOS brand name. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.
WILYY Company Deck
WILYY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced message: the company delivered solid cash generation, successful product launches (Zeal) and an acquisition that strengthens its Hearing Care footprint, while presenting a clear 2026 growth and profitability roadmap. At the same time, near-term profitability is pressured by a softer hearing aid market (especially in the U.S.), ASP/headwind mix effects, FX impacts, elevated leverage after the KIND acquisition, and planned restructuring/special items. Management expects the cost program and KIND contribution to support margin recovery in 2026, but risks (market softness, competitive pressure and FX) remain.View all WILYY earnings summariesTechnical Analysis
Insulet
―
Koninklijke Philips
―
Smith & Nephew Snats
―
Steris
―
Zimmer Biomet Holdings
―